[1] Frith JC, Mönkkönen J, Auriola S, et al.  The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis[J]. Arthritis Rheum, 2001, 44(9): 2201-2210.   doi: 10.1002/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E
[2] Luckman SP, Hughes DE, Coxon FP, et al.  Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras[J]. J Bone Miner Res, 1998, 13(4): 581-589.   doi: 10.1359/jbmr.1998.13.4.581
[3] Frith JC, Rogers MJ.  Antagonistic Effects of Different Classes of Bisphosphonates in Osteoclasts and Macrophages in Vitro[J]. J Bone Miner Res, 2003, 18(2): 204-212.   doi: 10.1359/jbmr.2003.18.2.204
[4] Bergstrom JD, Bostedor RG, Masarachia PJ, et al.  Alendronate is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate Synthase[J]. Arch Biochem Biophys, 2000, 373(1): 231-241.   doi: 10.1006/abbi.1999.1502
[5] Plotkin LI, Gortazar AR, Davis HM, et al.  Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor κB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading[J]. J Biol Chem, 2015, 290(31): 18934-18942.   doi: 10.1074/jbc.M115.642090
[6] Thompson K, Dunford JE, Ebetino FH, et al.  Identification of a Bisphosphonate that Inhibits Isopentenyl Diphosphate Isomerase and Farnesyl Diphosphate Synthase[J]. Biochem Biophys Res Commun, 2002, 290(2): 869-873.   doi: 10.1006/bbrc.2001.6289
[7] Cole LE, Vargo-Gogola T, Roeder RK.  Targeted delivery to bone and mineral deposits using bisphosphonate ligands[J]. Adv Drug Deliv Rev, 2016, 99(Pt A): 12-27.   doi: 10.1016/j.addr.2015.10.005
[8] Reyes C, Hitz M, Prieto-Alhambra D, et al.  Risks and Benefits of Bisphosphonate Therapies[J]. J Cell Biochem, 2016, 117(1): 20-28.   doi: 10.1002/jcb.25266
[9]

田源. 核医学微剂量估算系统[D]. 北京: 中国协和医科大学, 2008: 23.

Tian Y. The System of Microdosimetry Estimation in Nuclear Medicine[D]. Beijing: Peking Union Medical College, 2008: 23.
[10]

Pfannkuchen N, Meckel M, Bergmann R, et al. Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases[J/OL]. Pharmaceuticals (Basel), 2017, 10(2). pii: E45 [2020-01-09]. http://www.mdpi.com/resolver?pii=ph10020045. DOI: 10.3390/ph10020045.
[11] Howell RW, Wessels BW, Loevinger R, et al.  The MIRD perspective 1999. Medical Internal Radiation Dose Committee[J]. J Nucl Med, 1999, 40(1): 3S-10S.
[12] 项如莲, 陈其, 徐强, 等.  99Tcm和67Ga心肌显像在小儿病毒性心肌炎中的应用[J]. 中华核医学杂志, 2004, 24(5): 284-287.
Xiang RL, Chen Q, Xu Q, et al.  A clinical study of 99Tcm and 67Ga myocardial imaging in children with viral myocarditis[J]. Chin J Nucl Med, 2004, 24(5): 284-287.
[13] 邱艳芳, 赵艳萍.  骨转移瘤的影像学诊断研究现状[J]. 海南医学, 2015, 26(4): 543-546.   doi: 10.3969/j.issn.1003-6350.2015.04.0196
Qiu YF, Zhao YP.  Research status of imaging diagnosis of osseous metastatic tumor[J]. Hainan Med J, 2015, 26(4): 543-546.   doi: 10.3969/j.issn.1003-6350.2015.04.0196
[14] Rogers MJ, Gordon S, Benford HL, et al.  Cellular and molecular mechanisms of action of bisphosphonates[J]. Cancer, 2000, 88(12 Suppl): 2961-2978.   doi: 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L
[15] Tella SH, Gallagher JC.  Prevention and treatment of postmenopausal osteoporosis[J]. J Steroid Biochem Mol Biol, 2014, 142: 155-170.   doi: 10.1016/j.jsbmb.2013.09.008
[16]

张永学, 黄钢, 匡安仁, 等. 核医学[M]. 2版. 北京: 人民卫生出版社, 2010: 283.

Zhang YX, Huang G, Kuang AR, et al. Nuclear medicine[M]. 2nd ed. Beijing: People's Medical Publishing House, 2010: 283.
[17] Åkesson K, Marsh D, Mitchell PJ, et al.  Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle[J]. Osteoporos Int, 2013, 24(8): 2135-2152.   doi: 10.1007/s00198-013-2348-z
[18] Jaleel A, Saag KG, Danila MI.  Improving drug adherence in osteoporosis: an update on more recent studies[J]. Ther Adv Musculoskelet Dis, 2018, 10(7): 141-149.   doi: 10.1177/1759720X18785539
[19] Yazdanshenas H, Washington ER 3rd, Madadi F, et al.  Introducing and Prospective Efficacy Comparison of an Innovative and Affordable Technique for the Treatment of Distal Radius Fractures[J]. J Orthop, 2019, 16(6): 596-602.   doi: 10.1016/j.jor.2019.05.007
[20] Cairoli E, Zhukouskaya VV, Eller-Vainicher C.  Perspectives on osteoporosis therapies[J]. J Endocrinol Invest, 2015, 38(3): 303-311.   doi: 10.1007/s40618-014-0236-9
[21] 李慧敏, 方康权.  骨质疏松症的药物治疗研究进展[J]. 黑龙江医学, 2019, 43(5): 554-556.   doi: 10.3969/j.issn.1004-5775.2019.05.061
Li HM, Fang KQ.  Advances in drug treatment of osteoporosis[J]. Heilongjiang Med Sci, 2019, 43(5): 554-556.   doi: 10.3969/j.issn.1004-5775.2019.05.061
[22] 郝鹏飞, 霍建忠, 季兴华.  双膦酸盐类药物治疗骨质疏松症药物假期的研究进展[J]. 中华老年多器官疾病杂志, 2018, 17(7): 541-544.   doi: 10.11915/j.issn.1671-5403.2018.07.123
Hao PF, Huo JZ, Ji XH.  Research progress of bisphosphonate drug holiday in treatment of osteoporosis[J]. Chin J Mult Organ Dis Elder, 2018, 17(7): 541-544.   doi: 10.11915/j.issn.1671-5403.2018.07.123
[23] Criscitiello C, Viale G, Gelao L, et al.  Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment[J]. Cancer Treat Rev, 2015, 41(2): 61-68.   doi: 10.1016/j.ctrv.2014.12.001
[24] Sottnik JL, Dai J, Zhang H, et al.  Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases[J]. Cancer Res, 2015, 75(11): 2151-2158.   doi: 10.1158/0008-5472.CAN-14-2493
[25] Futakuchi M, Fukamachi K, Suzui M.  Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer[J]. Adv Drug Deliv Rev, 2016, 99(Pt B): 206-211.   doi: 10.1016/j.addr.2015.11.017
[26] Kellesarian SV, ALHarthi SS, Binshabaib MS, et al.  Effect of local zoledronate delivery on osseointegration: a systematic review of preclinical studies[J]. Acta Odontol Scand, 2017, 75(7): 530-541.   doi: 10.1080/00016357.2017.1350994
[27] 马文娟, 邹君惠, 杨智坚, 等.  骨组织修复及再生研究进展[J]. 实用医学杂志, 2016, 32(1): 151-153.   doi: 10.3969/j.issn.1006-5725.2016.01.049
Ma WJ, Zou JH, Yang ZJ, et al.  Progress in bone tissue repair and regeneration[J]. J Pract Med, 2016, 32(1): 151-153.   doi: 10.3969/j.issn.1006-5725.2016.01.049
[28] Fábián K, Puskás R, Kakuk T, et al.  Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis[J]. Basic Clin Pharmacol Toxicol, 2018, 122(1): 126-132.   doi: 10.1111/bcpt.12854
[29] Papamerkouriou YM, Kenanidis E, Gamie Z, et al.  Treatment of multiple myeloma bone disease: experimental and clinical data[J]. Expert Opin Biol Ther, 2015, 15(2): 213-230.   doi: 10.1517/14712598.2015.978853
[30] Van Acker HH, Anguille S, Willemen Y, et al.  Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials[J]. Pharmacol Ther, 2016, 158: 24-40.   doi: 10.1016/j.pharmthera.2015.11.008
[31] Xia LM, Huang WJ, Tian DA, et al.  Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression[J]. Hepatology, 2014, 59(3): 958-973.   doi: 10.1002/hep.26735
[32] Meraviglia S, Lo Presti E, Dieli F, et al.  γδ T cell-based anticancer immunotherapy: progress and possibilities[J]. Immunotherapy, 2015, 7(9): 949-951.   doi: 10.2217/imt.15.68
[33] Fromigue O, Lagneaux L, Body JJ.  Bisphosphonates Induce Breast Cancer Cell Death In Vitro[J]. J Bone Miner Res, 2000, 15(11): 2211-2221.   doi: 10.1359/jbmr.2000.15.11.2211
[34] 张众志, 陈璐璐, 李裕明.  二膦酸盐细胞分子作用机制的研究进展[J]. 中国骨质疏松杂志, 2004, 10(3): 390-392, 339.   doi: 10.3969/j.issn.1006-7108.2004.03.043
Zhang ZZ, Chen LL, Li YM.  Molecular mechanism of bisphosphonates[J]. Chin J Osteoporos, 2004, 10(3): 390-392, 339.   doi: 10.3969/j.issn.1006-7108.2004.03.043
[35] Bellahcène A, Bonjean K, Fohr B, et al.  Bone Sialoprotein Mediates Human Endothelial Cell Attachment and Migration and Promotes Angiogenesis[J]. Circ Res, 2000, 86(8): 885-891.   doi: 10.1161/01.RES.86.8.885
[36] Harper E, Forde H, Davenport C, et al.  Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL[J]. Vascul Pharmacol, 2016, 82: 30-40.   doi: 10.1016/j.vph.2016.02.003
[37] Kranenburg G, de Jong PA, Bartstra JW, et al.  Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum[J]. J Am Coll Cardiol, 2018, 71(10): 1117-1126.   doi: 10.1016/j.jacc.2017.12.062
[38] 何冰, 周欣, 郝倩, 等.  骨质疏松与动脉硬化性血管病相关机制的研究[J]. 中华老年心脑血管病杂志, 2012, 14(4): 438-440.   doi: 10.3969/j.issn.1009-0126.2012.04.032
He B, Zhou X, Hao Q, et al.  Mechanism of osteoporosis and arteriosclerotic vascular disease[J]. Chin J Geriatr Heart Brain Vessel Dis, 2012, 14(4): 438-440.   doi: 10.3969/j.issn.1009-0126.2012.04.032
[39]

李鑫宇. 新型双膦酸盐抑制5/6肾切除大鼠血管钙化的疗效观察[D]. 上海: 第二军医大学, 2012: 32.

Li XY. Efficacy of new bisphosphonate to inhibit vascular calcification in 5/6 nephrectomized rats[D]. Shanghai: The Second Military Medical University, 2012: 32.
[40] Price PA, Faus SA, Williamson MK.  Bisphosphonates Alendronate and Ibandronate Inhibit Artery Calcification at Doses Comparable to Those That Inhibit Bone Resorption[J]. Arterioscler Thromb Vasc Biol, 2001, 21(5): 817-824.   doi: 10.1161/01.ATV.21.5.817
[41] Eastell R, Newman C, Crossman DC.  Cardiovascular disease and bone[J]. Arch Biochem Biophys, 2010, 503(1): 78-83.   doi: 10.1016/j.abb.2010.06.008
[42] Maes C, Kobayashi T, Selig MK, et al.  Osteoblast Precursors, but Not Mature Osteoblasts, Move into Developing and Fractured Bones Along with Invading Blood Vessels[J]. Dev Cell, 2010, 19(2): 329-344.   doi: 10.1016/j.devcel.2010.07.010
[43] Coleman R, Hall A, Albanell J, et al.  Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial[J]. Lancet Oncol, 2017, 18(11): 1543-1552.   doi: 10.1016/S1470-2045(17)30603-4
[44] Abu-Id MH, Açil Y, Gottschalk J, et al.  Bisphosphonatassoziierte Osteonekrose des Kiefers[J]. Mund Kiefer Gesichtschir, 2006, 10(2): 73-81.   doi: 10.1007/s10006-005-0670-0
[45] Bamias A, Kastritis E, Bamia C, et al.  Osteonecrosis of the Jaw in Cancer After Treatment with Bisphosphonates: Incidence and Risk Factors[J]. J Clin Oncol, 2005, 23(34): 8580-8587.   doi: 10.1200/JCO.2005.02.8670
[46] Khan AA, Morrison A, Kendler DL, et al.  Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ[J]. J Clin Densitom, 2017, 20(1): 8-24.   doi: 10.1016/j.jocd.2016.09.005
[47] 彭诚.  双膦酸盐类药物治疗相关的下颌骨坏死的研究进展[J]. 医学综述, 2011, 17(8): 1181-1183.   doi: 10.3969/j.issn.1006-2084.2011.08.022
Peng C.  Progress in Study of Osteonecrosis of the Mandible Associated with Bisphosphonates Therapy[J]. Med Recapit, 2011, 17(8): 1181-1183.   doi: 10.3969/j.issn.1006-2084.2011.08.022
[48] 范晓莉.  恶性肿瘤骨转移诊断与治疗进展[J]. 临床合理用药杂志, 2009, 2(12): 92-94.   doi: 10.3969/j.issn.1674-3296.2009.12.071
Fan XL.  Progress in the diagnosis and treatment of malignant tumor bone metastasis[J]. Chin J Clin Rational Drug Use, 2009, 2(12): 92-94.   doi: 10.3969/j.issn.1674-3296.2009.12.071
[49] 林勤剑.  双磷酸盐及其功能化药物在骨转移诊断和治疗中的研究进展[J]. 实用医学杂志, 2018, 34(2): 172-175.   doi: 10.3969/j.issn.1006-5725.2018.02.002
Lin QJ.  Research progress of bisphosphonates and their functional drugs in the diagnosis and treatment of bone metastasis[J]. J Pract Med, 2018, 34(2): 172-175.   doi: 10.3969/j.issn.1006-5725.2018.02.002
[50] Guven MN, Seckin Altuncu M, Demir Duman F, et al.  Bisphosphonate-functionalized poly(β-amino ester) network polymers[J]. J Biomed Mater Res A, 2017, 105(5): 1412-1421.   doi: 10.1002/jbm.a.36026
[51] Kootala S, Ossipov D, van den Beucken JJJP, et al.  Correction: Bisphosphonate-functionalized hyaluronic acid showing selective affinity for osteoclasts as a potential treatment for osteoporosis[J]. Biomater Sci, 2015, 3(10): 1414-.   doi: 10.1039/C5BM90034D